Open Access. Powered by Scholars. Published by Universities.®
Pathological Conditions, Signs and Symptoms Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- 3rd level students (1)
- AHUS (1)
- Anaemia (1)
- Anaphylaxis (1)
- Aspirin (1)
-
- BRCA (1)
- Bortezomib (1)
- COVID-19 (1)
- CTTP (1)
- Cancer (1)
- Cardiotoxicity (1)
- Carfilzomib (1)
- Checkpoint inhibitors (1)
- Coagulopathy (1)
- Coronavirus (1)
- Cytokine storm (1)
- DHUS (1)
- Diabetes (1)
- Dialysis (1)
- Dietetic service (1)
- Eculizumab (1)
- Food allergen (1)
- Food allergy (1)
- Gene (1)
- Genetic screening (1)
- Haemolysis (1)
- Health sciences (1)
- Hyperglycaemia (1)
- ITTP (1)
- Ibuprofen (1)
- Publication
- Publication Type
Articles 1 - 2 of 2
Full-Text Articles in Pathological Conditions, Signs and Symptoms
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
Full Issue: The International Undergraduate Journal Of Health Sciences, Volume 1, Issue 1, June 2021
International Undergraduate Journal of Health Sciences
The full June 2021 issue (Volume 1, Issue 1) of the International Undergraduate Journal of Health Sciences
The Effect Of Carfilzomib And Bortezomib Based Regimes On Cardiotoxicity In Multiple Myeloma Patients At Cooper University Hospital, Ami Patel, Tulin Budak-Alpdogan, Stalam Tapati
The Effect Of Carfilzomib And Bortezomib Based Regimes On Cardiotoxicity In Multiple Myeloma Patients At Cooper University Hospital, Ami Patel, Tulin Budak-Alpdogan, Stalam Tapati
Rowan-Virtua Research Day
Introduction
- Multiple myeloma (MM) is a cancer of plasma cells, which is a white blood cell that normally produces antibodies
- Treatment in patients younger than 65 years old is typically high dose chemotherapy, usually with bortezomib based regimens or lenalidomide dexamethasone, followed by a stem cell transplant
- For patients with relapsed myeloma, carfilzomib is usually the treatment of choice
- Carfilzomib is a highly selective, irreversible proteasome inhibitor that binds to the 20 S proteasome. Several studies have illustrated that carfilzomib has been associated with cardiovascular adverse events (CVAE).
- Current literature on the role and effect of bortezomib on cardiotoxicity is …